Supplementary Figure 3 from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions
Year: 2023
Type: supplementary-materials
Abstract: Figure S3. MIR300 acts as master PP2A activator and inhibitor of G1/S transition. A, (left) Additional effects of MIR300 on SET, CCND2 and CDK6 expression; (right) KEGG/GO analysis of MIR300 effects on signal transduction pathways. B, CSmiRTar (filters: bone marrow normal and myeloid leukemia cells) and miRDIP-ComiR integrated analyses show functional clustering of predicted/validated MIR300 targets.
Authors: Giovannino Silvestri, Rossana Trotta, Lorenzo Stramucci, Justin J. Ellis, Jason G. Harb, Paolo Neviani, Shuzhen Wang, Ann-Kathrin Eisfeld, Christopher J. Walker, Bin Zhang, Klara Srutova, Carlo Gambacorti-Passerini, Gabriel Pineda, Catriona H. M. Jamieson, Fabio Stagno, Paolo Vigneri, Georgios Nteliopoulos, Philippa C. May, Alistair G. Reid, Ramiro Garzon, Denis-Claude Roy, Moutuaata M. Moutuou, Martin Guimond, Peter Hokland, Michael W. Deininger, Garrett Fitzgerald, Christopher Harman, Francesco Dazzi, Dragana Milojkovic, Jane F. Apperley, Guido Marcucci, Jianfei Qi, Katerina Machova Polakova, Ying Zou, Xiaoxuan Fan, Maria R. Baer, Bruno Calabretta, Danilo Perrotti
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361255652